MoHAP Signs Agreement with Novo Nordisk Pharma Gulf
The Ministry of Health and Prevention (MoHAP) has teamed up with Novo…
Lancet Study: Semaglutide Reduces Risk of CV Death and Worsening Heart Failure
PLAINSBORO, N.J- Recently, The Lancet published a new pooled, participant-level analysis of patients…
Could single-Dose Zepbound Vials be a game-changer for weight loss?
August 2024- Eli Lilly and Company announced Zepbound ® (tirzepatide) 2.5 mg…
MoHAP trains school health staff to combat childhood obesity
August 2024- The Ministry of Health and Prevention (MoHAP) has organized a…
Screen Time vs. Green Time: Why Prioritizing Outdoor Play is Crucial for Children’s Health
While technology offers many benefits by being more accessible and convenient to…
Move It or Lose It! Nearly Half the World Needs More Exercise
Geneva- 26 June 2024- New data show that nearly one-third (31%) of…
Pre-Kidney Transplant Weight-loss Surgery Boosts Patient Health: Mayo Clinic Study
ROCHESTER, Minn. — Laparoscopic sleeve gastrectomy promotes relatively rapid weight loss, reduces obesity-related health…
One in eight people are now living with obesity
March 2024- New study released by the Lancet shows that, in 2022,…
Pfizer’s Promising Oral Treatment for Obesity Shows Positive Phase 2b Results
New York- Pfizer Inc. has announced promising topline data from its Phase…
FDA Approves Eli Lilly’s Zepbound™ for Obesity Treatment
INDIANAPOLIS: Eli Lilly and Company's (NYSE: LLY) innovative obesity treatment, Zepbound™ (tirzepatide)…